



PATENT ATTORNEY DOCKET NO. 04585/048002

Certificate of Mailing: Date of Deposit: May 14, 2002

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to the U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202.

Mary Jane DiPalma

Printed name of person mailing correspondence

berson mailing correspondence Signature of

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Robert N. McBurney et al.

Art Unit:

1646

Serial No.:

09/530,884

Examiner:

Michael T. Branno

Filed:

August 29, 2000

Customer No.:

21559

Title:

THERAPEUTIC METHODS COMPRISING USE OF A NEUREGULIN

U.S. Patent and Trademark Office

Box Sequence

P.O. Box 2327

Arlington, VA 22202

STATEMENT UNDER 37 C.F.R. § 1.825(d)

In reply to the Notice to Comply mailed March 21, 2002, enclosed is a substitute copy of the sequence listing in computer readable form, the contents of which are identical to that filed on January 3, 2002.

If there are any charges, or any credits, please apply them to Deposit Account No. 03-2095.

Clark & Elbing LLP 101 Federal Street Boston, MA 02110

Telephone: 617-428-0200 Facsimile: 617-428-7045

Respectfully submitted,

Application No.: 09530884

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

MAY 17 2002

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

| X | 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990. |
|-------------------------|---|
| | 2. This application does not contain, as a separate part of the disclosure on paper cop a "Sequence Listing" as required by 37 C.F.R. 1.821(c). |
| | 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). |
| X | 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 G.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the Raw Sequence Listing Error Report. |
| | 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). |
| | 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e). |
| П | 7. Other: |
| Applicant Must Provide: | |
| X | An initial or substitute computer readable form (CRF) copy of the "Sequence Listing". |
| | An initial or <u>substitute</u> paper copy of the "Sequence Listing", <u>as well as an amendment directing its entry into the specification</u> . |
| х | A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d). |
| For | questions regarding compliance to these requirements, please contact: |
| | Rules Interpretation, call (703) 308-4216 |
| | CRF Submission Help, call (703) 308-4212 |
| Ł OI | Patentin software help, call (703) 308-6856 PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE |